Sharing Helps: How Reporting to the TGA Supports the MS Community
2 September 2025
Reporting side effects, even minor ones, is one way people with MS can contribute to safer treatment for everyone.
Reporting side effects, even minor ones, is one way people with MS can contribute to safer treatment for everyone.
CEO Rohan Greenland details the upcoming handover of the Blueprint for a National Action Plan for Neurological Conditions, a prod to government to recognise both the obligation and the economic imperative to deliver coordinated national action.
A new Australian study shows COVID-19 boosters improve protection against new variants for people with MS, even when taking immune-suppressing treatments.
People living with MS find MSReactor is a convenient and acceptable way to monitor changes in their thinking and memory over time.
The Pharmaceutical Benefits Advisory Committee has recommended subcutaneous ocrelizumab (Ocrevus®) be listed on the PBS for treating relapsing remitting MS.
The Government has announced changes to the NDIS aimed at slowing growth and making the scheme more sustainable. What are those changes and how will they impact Australians living with MS?
MS Australia announces the four recipients of the first round of Incubator Grants for 2025.
A world-first Australian study is using DNA to identify a person’s genetic risk of developing multiple sclerosis (MS) to understand how their immune system responds to a common virus linked to the disease.Â
MS Australia is calling on the government to improve the aged care system to better meet the needs of older people with disability and reaffirm their commitment to reduce wait times for home care packages.